Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company
21 Mar 24
6-K
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
12 Feb 24
6-K
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
9 Jan 24
6-K
Current report (foreign)
8 Jan 24
6-K
MediWound Secures Additional U.S. Department of Defense Funding to
28 Dec 23
6-K
Current report (foreign)
15 Dec 23
6-K
MediWound Reports Third Quarter 2023 Financial Results and Provides
21 Nov 23
6-K
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer
21 Nov 23
6-K
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
13 Nov 23
6-K
MediWound Secures Additional U.S. Department of Defense Funding to
26 Sep 23
6-K
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
21 Sep 23
S-8
Registration of securities for employees
15 Aug 23
6-K
MediWound Reports Second Quarter 2023 Financial Results and Provides
15 Aug 23
6-K
Current report (foreign)
15 Aug 23
6-K
Current report (foreign)
2 Aug 23
6-K
Current report (foreign)
17 Jul 23
6-K
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005
10 Jul 23
6-K
MediWound Receives Positive Scientific Advice from European Medicine
3 Jul 23
6-K
Current report (foreign)
31 May 23
6-K
Current report (foreign)
31 May 23
6-K
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
30 May 23
6-K
MediWound Announces an Additional $10 Million Award from BARDA
9 May 23
6-K
Current report (foreign)
20 Apr 23
424B3
Prospectus supplement
6 Apr 23
EFFECT
Notice of effectiveness
6 Apr 23
POS AM
Prospectus update (post-effective amendment)
31 Mar 23
6-K
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and 2022 total revenues of $26.5 million
16 Mar 23
POS EX
Additional exhibits for listing
16 Mar 23
424B3
Prospectus supplement
16 Mar 23
20-F
2022 FY
Annual report (foreign)
16 Mar 23
424B3
Prospectus supplement
16 Mar 23
6-K
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
16 Mar 23
6-K
Current report (foreign)
13 Feb 23
6-K
Current report (foreign)
7 Feb 23
424B5
Prospectus supplement for primary offering
3 Feb 23
424B3
Prospectus supplement
9 Jan 23
6-K
Current report (foreign)
9 Jan 23
424B3
Prospectus supplement
6 Jan 23
6-K
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
29 Dec 22
Latest ownership filings
SC 13G/A
Rosalind Advisors, Inc.
25 Apr 24
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24
SC 13G/A
Deep Insight Limited Partnership
8 Jan 24
SC 13G/A
Israel Biotech Fund II, L.P.
8 Jan 24
SC 13D/A
Access Industries Holdings LLC
1 Sep 23
SC 13G/A
ROSENBERG LIOR
14 Feb 23
SC 13D/A
Access Industries Holdings LLC
13 Feb 23
SC 13G
Point72 Asset Management, L.P.
8 Feb 23
SC 13G
Rosalind Advisors, Inc.
21 Dec 22
SC 13G
Deep Insight Limited Partnership
5 Dec 22
SC 13G
Israel Biotech Fund II, L.P.
5 Dec 22
SC 13D/A
Access Industries Holdings LLC
26 Sep 22
SC 13D/A
Access Industries Holdings LLC
1 Jul 22
SC 13D
Access Industries Holdings LLC
17 Mar 22
SC 13G/A
ROSENBERG LIOR
14 Feb 22
SC 13G
Migdal Insurance & Financial Holdings Ltd.
2 Feb 22
SC 13G
Migdal Insurance & Financial Holdings Ltd.
16 Feb 21
SC 13G/A
ROSENBERG LIOR
2 Feb 21
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
9 Jun 20
SC 13G
MediWound Ltd.
6 Feb 20
SC 13G/A
MediWound Ltd.
5 Feb 20
SC 13G/A
Beneficial ownership report (amended)
28 Jan 20
SC 13G/A
MediWound Ltd.
27 Jan 20
SC 13G/A
MediWound Ltd.
14 Feb 19
SC 13G
MediWound Ltd.
14 Feb 19
SC 13G/A
MediWound Ltd.
12 Feb 19
SC 13G/A
MediWound Ltd.
12 Feb 19
SC 13G/A
MediWound Ltd.
11 Feb 19
SC 13G/A
MediWound Ltd.
6 Feb 19
SC 13G/A
MediWound Ltd.
14 Feb 18
SC 13G/A
MediWound Ltd.
8 Feb 18
SC 13G/A
MediWound Ltd.
8 Feb 18
SC 13G/A
MediWound Ltd.
6 Feb 18
SC 13G/A
MediWound Ltd.
31 Jan 18
SC 13G
MediWound Ltd.
22 Jan 18
SC 13G
MediWound Ltd.
5 Sep 17
SC 13G/A
MediWound Ltd.
10 Aug 17
SC 13G/A
MediWound Ltd.
14 Feb 17
SC 13G
MediWound Ltd.
9 Feb 17
SC 13G/A
MediWound Ltd.
7 Feb 17